Brain imaging platform could ‘accelerate’ tumour treatment
An advanced imaging platform could “accelerate” the treatment of childhood brain tumours, research reveals.
Scientists at The Institute of Cancer Research, London have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen in patients.
Researchers led work to develop a large panel of patient-derived mouse models of paediatric-type diffuse high-grade glioma (PDHGG) – a group of brain tumours with poor survival rates. Using magnetic resonance imaging (MRI), the research team demonstrated that these models reproduce key biological and radiological features of the human disease.
The study, published in Neuro-Oncology Advances and primarily funded by Cancer Research UK, provides a new framework for testing potential therapies and monitoring tumour response to closely reflect what happens in the clinic – helping researchers identify the most promising treatments for patients more quickly.
“For children and families affected by these aggressive brain tumours, the ultimate aim is to accelerate the development of treatments that can finally improve survival,” said Professor Simon Robinson, Senior Author and Group Leader of the Pre-Clinical MRI Group.
“This imaging-led approach brings us a step closer to that goal.”
Imaging highlights ‘major obstacle’ for drug delivery
PDHGGs, aggressive and fast-growing brain cancers, are among the leading causes of cancer-related morbidity and mortality in children and young adults. In most cases, median survival is only nine to 18 months, with two- and five-year survival rates as low as 10 and two per cent, respectively.
Despite decades of research, outcomes have largely remained unchanged. This is primarily because these tumours are biologically distinct from other adult brain cancers with similar presentation, and they are difficult to model accurately in the laboratory.
To address this, the research team established 35 patient-derived, site-specific tumour models by implanting tumour material into the equivalent locations in the brains of mice. The models represent a range of PDHGG subtypes, including diffuse midline glioma (DMG) and diffuse hemispheric glioma (DHG).
Survival times varied widely across the models, reflecting the diversity seen in patients. While some tumours grew slowly over many months, others progressed more rapidly – an important feature to observe for testing new treatments.
Rather than relying solely on tissue analysis at the end of the experiment the researchers used non-invasive MRI to track tumour growth and behaviour over time. This approach allowed them to assess the size and structure of the tumour and the integrity of the blood-brain barrier – all vital factors in treatment response.
A key finding was that most tumours did not light up on MRI scans after a contrast agent was given, showing that the blood-brain barrier was still intact and blocking substances from entering the tumour – a major obstacle for drug delivery in patients.
This was specifically true for tumours in the brainstem – the area connecting the brain to the spinal cord – mirroring clinical observations of being harder to treat and emphasising the importance of testing therapies in models that reflect this challenge.
Platform ‘lays the groundwork’ for therapy development
The research team also examined whether tumours changed as they were re-implanted into new mice, a common step in maintaining experimental models. While some tumours grew faster when re-implanted, most retained the characteristics seen with MRI, suggesting that their fundamental biological features and appearance remained stable.
In a further set of experiments, tumours grown from cells cultured in three-dimensional conditions showed shorter survival and higher proliferation than those grown in traditional two-dimensional cultures. This demonstrates how laboratory growth conditions can influence behaviour and reinforces the value of carefully designed preclinical systems.
By combining patient-derived tumours with clinically relevant MRI techniques, the platform enables researchers to evaluate whether new drugs reach the tumour, alter its biology and produce meaningful changes over time.
“This research lays important groundwork for future therapy development,” said Dr Jessica Boult, Staff Scientist in the Pre-Clinical MRI Group at The Institute of Cancer Research (ICR).
“If we want to improve outcomes for children and young adults with these tumours, we need models that genuinely reflect the disease – not just at the molecular level but in how tumours grow, spread and respond to treatment. Embedding advanced imaging into these models allows us to do that.”
